Traders display unanimous conviction on Polymarket that Theravance Biopharma (TBPH) will beat quarterly earnings, with "Yes" implied probability at 100%, propelled by the biotech's reliable royalty revenue from Yupelri (revefenacin), which surged 45% year-over-year in Q2 to $14.5 million, handily surpassing consensus estimates. Conservative Wall Street forecasts—EPS at -$0.37 for Q3—reflect biotech headwinds, yet TBPH's track record of four straight quarterly beats and stable partner Viatris sales underpin this capital-backed consensus ahead of the November 7 release. Tail risks remain slim but include clinical setbacks in treprostinil programs or unexpected royalty dips, though historical resilience mutes these concerns.
基於Polymarket數據的AI實驗性摘要 · 更新於是
$0.00 交易量
$0.00 交易量
Feb 25, 2026
是
$0.00 交易量
$0.00 交易量
Feb 25, 2026
As of market creation, Theravance Biopharma is estimated to release earnings on February 25, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $1.01 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $1.01 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Theravance Biopharma is estimated to release earnings on February 25, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $1.01 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $1.01 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Theravance Biopharma is estimated to release earnings on February 25, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $1.01 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $1.01 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
市場開放時間： Feb 16, 2026, 5:51 PM ET
交易量
$0結束日期
Feb 25, 2026市場開放時間
Feb 16, 2026, 5:51 PM ETResolution Source
https://seekingalpha.com/Resolver
0x65070BE91...已提議結果: 是
無爭議
最終結果: 是
As of market creation, Theravance Biopharma is estimated to release earnings on February 25, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $1.01 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $1.01 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Theravance Biopharma is estimated to release earnings on February 25, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $1.01 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $1.01 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Theravance Biopharma is estimated to release earnings on February 25, 2026. The Street consensus estimate for Theravance Biopharma's GAAP EPS for the relevant quarter is $1.01 as of market creation. This market will resolve to "Yes" if Theravance Biopharma reports GAAP EPS greater than $1.01 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Theravance Biopharma releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
交易量
$0結束日期
Feb 25, 2026市場開放時間
Feb 16, 2026, 5:51 PM ETResolution Source
https://seekingalpha.com/Resolver
0x65070BE91...已提議結果: 是
無爭議
最終結果: 是
Traders display unanimous conviction on Polymarket that Theravance Biopharma (TBPH) will beat quarterly earnings, with "Yes" implied probability at 100%, propelled by the biotech's reliable royalty revenue from Yupelri (revefenacin), which surged 45% year-over-year in Q2 to $14.5 million, handily surpassing consensus estimates. Conservative Wall Street forecasts—EPS at -$0.37 for Q3—reflect biotech headwinds, yet TBPH's track record of four straight quarterly beats and stable partner Viatris sales underpin this capital-backed consensus ahead of the November 7 release. Tail risks remain slim but include clinical setbacks in treprostinil programs or unexpected royalty dips, though historical resilience mutes these concerns.
基於Polymarket數據的AI實驗性摘要 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions